Olivbood
☆    

France,
2019-06-14 10:42
(493 d 21:06 ago)

Posting: # 20325
Views: 1,471
 

 Minimal Sample Size for Food Effect Study [Regulatives / Guidelines]

Hello everyone,

I have a relatively quick question in regards to the FDA guideline "Assessing the Effects of Food on Drugs in INDs and NDAs — Clinical Pharmacology Considerations" dated February 2019.

The guideline specifies that "At a minimum, 12 subjects should be enrolled in each treatment arm." I deduce from it that this is the minimal sample size considering a parallel design study.
Alternatively, for a classic 2x2 cross-over study the minimal sample size should be 12 subjects in total since each subject will experience both fed and fasted status.

Is my understanding correct?

Many thanks,

Olivbood


Edit: Guidance linked. [Helmut]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2019-06-14 20:43
(493 d 11:04 ago)

@ Olivbood
Posting: # 20327
Views: 1,200
 

 Parallel: 2×12, Xover: 12

Hi Olivbood,

» The guideline specifies that "At a minimum, 12 subjects should be enrolled in each treatment arm." I deduce from it that this is the minimal sample size considering a parallel design study.

Correct.

» Alternatively, for a classic 2x2 cross-over study the minimal sample size should be 12 subjects in total since each subject will experience both fed and fasted status.
»
» Is my understanding correct?

Correct, again.

I both cases I would include a bit more subjects to be protected against eventual dropouts. I guess the FDA wouldn’t be amused to get a study in 11 subjects although the guidance clearly states “12 enrolled”.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Activity
 Admin contact
21,164 posts in 4,410 threads, 1,476 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Tuesday 07:48 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5